Screener
Allogene Therapeutics ALLO Business Segments — Income Tax
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Allogene Therapeutics’s 10-K, filed March 12, 2026.
- Filed
- Mar 12, 2026, 4:11 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001628280-26-017242
| Line item | Years Ended December 31, 2025 | Years Ended December 31, 2024 |
|---|---|---|
| Facilities & IT-related spend | 28,408 | 31,727 |
| Supporting external spend | 20,698 | 27,337 |
| Other operating expenses | 53,590 | 82,989 |
| Total operating expenses | 209,315 | 273,221 |
| Other income (Expense), net | 18,429 | 16,052 |
| Loss before income taxes | (190,886) | (257,147) |
| Benefit (expense) from income taxes | — | (443) |
| Net loss | (190,886) | (257,590) |
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is Allogene Therapeutics's business segments — income tax?
- Allogene Therapeutics (ALLO) reported business segments — income tax of $0 in Q4 2025.
- How has Allogene Therapeutics's business segments — income tax changed year-over-year?
- Allogene Therapeutics's business segments — income tax decreased by 100.0% year-over-year, from $110.75K to $0.
- What does business segments — income tax mean?
- This metric reflects the portion of total corporate income tax liability specifically allocated or attributable to the operations of a distinct business segment. It captures the tax impact of segment-level earnings or losses, providing insight into the tax efficiency of the segment's activities. Monitoring this helps stakeholders understand how tax regulations and jurisdictional requirements influence the net contribution of individual business units to the company's bottom line.
Ask your AI about Allogene Therapeutics's business segments — income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude